The Hepatitis B Virus Infection Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Hepatitis B Virus Infection treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the pipeline landscape and fostering the potential growth of Hepatitis B Virus Infection therapeutic advancements.

 

Key Takeaways from the Hepatitis B Virus Infection Pipeline Report

• DelveInsight’s Hepatitis B Virus Infection pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Hepatitis B Virus Infection treatment.
• The leading companies working in the Hepatitis B Virus Infection market include Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
• Promising Hepatitis B Virus Infection Pipeline Therapies in the various stages of development include EYP001a, VIR-2218, Pegylated interferon-alfa 2a, VIR-2218, VIR-3434, PEG-IFNα, ABI-H3733, NCO-48 Fumarate 4 mg, Tenofovir Alafenamide 25 mg, and others.
• On January 2023, Nucorion Pharmaceuticals Inc. announced a study of phase 1 clinical trials for NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg and Tenofovir Alafenamide 25 mg. This is an open-label study evaluating multiple doses of NCO-48 Fumarate versus tenofovir alafenamide (TAF).
• On February 2023, Vir Biotechnology Inc. announced a study of phase 2 clinical trials for VIR-2218 and pegylated interferon-alfa 2a. This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
• On June 2023, Assembly Biosciences announced a study of phase 1 clinical trials for ABI-H3733. This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-H3733 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis B e antigen (HBeAg) positive or negative. The study will enroll up to 5 sequential cohorts of 10 subjects each, for a total of up to 50 subjects, randomized 8:2 to receive ABI-H3733 or placebo.
• On August 2023, Janssen Research & Development LLC announced a study of phase 2 clinical trials for JNJ-73763989, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), and PegIFN-alpha-2a (Optional). The purpose of this study is to assess changes in intrahepatic hepatitis B surface antigen (HBsAg) between baseline and on-treatment liver biopsy in response to JNJ-3989-based combination treatment.

 

Request a sample and discover the recent advances in Hepatitis B Virus Infection Treatment Drugs @ Hepatitis B Virus Infection Pipeline Report

 

The Hepatitis B Virus Infection pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Hepatitis B Virus Infection drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Hepatitis B Virus Infection clinical trial landscape.

 

Hepatitis B Virus Infection Overview

Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). The Hepatitis B virus is transmitted via percutaneous inoculation or through mucosal exposure with infectious bodily fluids.

 

Find out more about Hepatitis B Virus Infection Treatment Drugs @ Drugs for Hepatitis B Virus Infection Treatment

 

Hepatitis B Virus Infection Emerging Drugs Profile

• Bepirovirsen: GSK
• VIR 2218: Vir Biotechnology
• AB 729: Arbutus Biopharma
• AHB-137: Ausper Biopharma

 

Hepatitis B Virus Infection Pipeline Therapeutics Assessment

The Hepatitis B Virus Infection pipeline report proffers an integral view of the Hepatitis B Virus Infection emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Hepatitis B Virus Infection Pipeline Therapies @ Hepatitis B Virus Infection Clinical Trials Assessment

 

Scope of the Hepatitis B Virus Infection Pipeline Report

• Coverage- Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Companies- Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
• Pipeline Therapies- EYP001a, VIR-2218, Pegylated interferon-alfa 2a, VIR-2218, VIR-3434, PEG-IFNα, ABI-H3733, NCO-48 Fumarate 4 mg, Tenofovir Alafenamide 25 mg, and others.

 

Dive deep into rich insights for new drugs for Hepatitis B Virus Infection treatment, Visit @ Hepatitis B Virus Infection Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Hepatitis B Virus Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hepatitis B Virus Infection– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Bepirovirsen: GSK
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. VIR 2218: Vir Biotechnology
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AHB-137: Ausper Biopharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hepatitis B Virus Infection Key Companies
21. Hepatitis B Virus Infection Key Products
22. Hepatitis B Virus Infection- Unmet Needs
23. Hepatitis B Virus Infection- Market Drivers and Barriers
24. Hepatitis B Virus Infection- Future Perspectives and Conclusion
25. Hepatitis B Virus Infection Analyst Views
26. Hepatitis B Virus Infection Key Companies
27. Appendix

 

For further information on the Hepatitis B Virus Infection pipeline therapeutics, reach out @ Hepatitis B Virus Infection Unmet Needs and Analyst Views

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking